What is LOPJLB’s current signal on IRLA?

LOPJLB’s latest quantitative signal on IRulya Therapeutics Inc. (IRLA) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is IRLA in?

IRulya Therapeutics Inc. (IRLA) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does IRulya Therapeutics Inc. (IRLA) do?

IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.

IRulya Therapeutics Inc. (IRLA)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$30.00+7.64%Close

SELLRECOVERY · day 5

Loading earnings…

FAQ

What is LOPJLB’s current signal on IRLA?: LOPJLB’s latest quantitative signal on IRulya Therapeutics Inc. (IRLA) is SELL in a RECOVERY regime. Signals are updated daily.
What market regime is IRLA in?: IRulya Therapeutics Inc. (IRLA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does IRulya Therapeutics Inc. (IRLA) do?: IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.

IRulya Therapeutics Inc. (IRLA)

Key stats

Prediction markets

EARNINGS HISTORY

Company news

FAQ